{
    "root": "9ea0f8c6-1a02-49e3-91e1-05d3f75f569d",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Diclofenac Potassium",
    "value": "20250203",
    "ingredients": [
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "DICLOFENAC POTASSIUM",
            "code": "L4D5UA6CB4"
        }
    ],
    "indications": "carefully consider potential benefits risks diclofenac potassium immediate-release tablets treatment options deciding diclofenac potassium tablets . lowest effective dose shortest duration consistent individual patient treatment goals ( ; gastrointestinal bleeding , ulceration , perforation ) . diclofenac potassium tablets indicated : treatment primary dysmenorrhea relief mild moderate pain relief signs symptoms osteoarthritis relief signs symptoms rheumatoid arthritis",
    "contraindications": "carefully consider potential benefits risks diclofenac potassium immediate-release tablets treatment options deciding diclofenac potassium tablets . lowest effective dose shortest duration consistent individual patient treatment goals ( ; gastrointestinal bleeding , ulceration , perforation ) . observing response initial therapy diclofenac potassium tablets , dose frequency adjusted suit individual patient ’ needs . treatment pain primary dysmenorrhea recommended 50 mg three times day . experience , physicians may find patients initial dose 100 mg diclofenac potassium tablets , followed 50-mg doses , provide better relief . relief osteoarthritis recommended 100 150 mg/day divided doses , 50 mg twice day . three times day . relief rheumatoid arthritis recommended 150 200 mg/day divided doses , 50 mg three times day four times day . different formulations diclofenac [ voltaren ® ( diclofenac sodium enteric-coated tablets ) ; voltaren ®-xr ( diclofenac sodium extended-release tablets ) ; diclofenac potassium immediate release tablets ] necessarily bioequivalent even milligram strength .",
    "warningsAndPrecautions": "diclofenac potassium tablets , usp available containing 50 mg diclofenac potassium , usp . 50 mg tablets white off-white , round , biconvex , film coated tablets debossed 'dp ' one side '50 ' side . ndc 71335-9720-1 : 20 tablets bottle ndc 71335-9720-2 : 90 tablets bottle ndc 71335-9720-3 : 30 tablets bottle ndc 71335-9720-4 : 60 tablets bottle ndc 71335-9720-5 : 45 tablets bottle ndc 71335-9720-6 : 58 tablets bottle ndc 71335-9720-7 : 18 tablets bottle ndc 71335-9720-8 : 120 tablets bottle store dispense tight , light- resistant container defined usp . store room temperature 20°c 25°c ( 68°f 77°f ) ; excursions permitted 15°c 30°c ( 59°f 86°f ) [ usp controlled room temperature ] . protect moisture repackaged/relabeled : bryant ranch prepack , inc.burbank , ca 91504",
    "adverseReactions": "diclofenac potassium tablets contraindicated following patients : known hypersensitivity ( e.g . , anaphylactic serious skin ) diclofenac components product ( ; anaphylactic , serious skin ) . history asthma , urticaria , allergic-type taking aspirin nsaids . severe , sometimes fatal , anaphylactic nsaids reported patients ( ; anaphylactic , exacerbation asthma related aspirin sensitivity ) . setting coronary artery bypass graft ( cabg ) surgery ( ; cardiovascular thrombotic events ) .",
    "indications_original": "Carefully consider the potential benefits and risks of diclofenac potassium immediate-release tablets and other treatment options before deciding to use diclofenac potassium tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see\n \n  WARNINGS; Gastrointestinal Bleeding, Ulceration, and Perforation). \n    Diclofenac potassium tablets are indicated:\n\n \n                  \n                     For treatment of primary dysmenorrhea\n                  \n                  \n                     For relief of mild to moderate pain\n                  \n                  \n                     For relief of the signs and symptoms of osteoarthritis\n                  \n                  \n                     For relief of the signs and symptoms of rheumatoid arthritis",
    "contraindications_original": "Carefully consider the potential benefits and risks of diclofenac potassium immediate-release tablets and other treatment options before deciding to use diclofenac potassium tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see\n \n  WARNINGS; Gastrointestinal Bleeding, Ulceration, and Perforation). \n  \n                       After observing the response to initial therapy with diclofenac potassium tablets, the dose and frequency should be adjusted to suit an individual patient’s needs. \n  \n                       For treatment of pain or primary dysmenorrhea the recommended dosage is 50 mg three times a day. With experience, physicians may find that in some patients an initial dose of 100 mg of diclofenac potassium tablets, followed by 50-mg doses, will provide better relief. \n  \n                       For the relief of osteoarthritis the recommended dosage is 100 to 150 mg/day in divided doses, 50 mg twice a day. or three times a day. \n  \n                       For the relief of rheumatoid arthritis the recommended dosage is 150 to 200 mg/day in divided doses, 50 mg three times a day or four times a day. \n  \n                       Different formulations of diclofenac [VOLTAREN\n \n  ®(diclofenac sodium enteric-coated tablets); Voltaren\n \n  ®-XR (diclofenac sodium extended-release tablets); diclofenac potassium immediate release tablets] are not necessarily bioequivalent even if the milligram strength is the same.",
    "warningsAndPrecautions_original": "Diclofenac Potassium Tablets, USP are available containing 50 mg of diclofenac potassium, USP.\n                  The 50 mg tablets are white to off-white, round, biconvex, film coated tablets debossed with 'DP' on one side and '50' on other side.\n                  \n                     NDC 71335-9720-1: 20 Tablets in a BOTTLE\n                     NDC 71335-9720-2: 90 Tablets in a BOTTLE\n                     NDC 71335-9720-3: 30 Tablets in a BOTTLE\n                     NDC 71335-9720-4: 60 Tablets in a BOTTLE\n                     NDC 71335-9720-5: 45 Tablets in a BOTTLE\n                     NDC 71335-9720-6: 58 Tablets in a BOTTLE\n                     NDC 71335-9720-7: 18 Tablets in a BOTTLE\n                     NDC 71335-9720-8: 120 Tablets in a BOTTLE\n                  \n                  Store and dispense in tight, light- resistant container as defined in the USP.\n                  Store at room temperature 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Protect from moisture\n                  Repackaged/Relabeled by:Bryant Ranch Prepack, Inc.Burbank, CA 91504",
    "adverseReactions_original": "Diclofenac potassium tablets are contraindicated in the following patients:\n                  \n                     Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac or any components of the drug product (see\n  \n   \n                        WARNINGS; Anaphylactic Reactions, Serious Skin Reactions).\n \n  \n                     History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients (\n  \n   see WARNINGS; Anaphylactic Reactions, Exacerbation of Asthma Related to Aspirin Sensitivity).\n \n  \n                     In the setting of coronary artery bypass graft (CABG) surgery (\n  \n   see WARNINGS; Cardiovascular Thrombotic Events)."
}